Table 2: Noncost inputs for cost effectiveness analysis model.

Inputs Estimate Source Prevalence of VAP among ventilated patients 0.227 Matched cohort study Case fatality ratio (CFR) for VAP cases 0.5 Matched cohort study CFR for controls 0.1 Matched cohort study Average length of stay (LOS): VAP case in days 27.9 Matched cohort study Average LOS: controls in days 10.9 Matched cohort study Average number of cultures: VAP cases 5.96 Matched cohort study Average number of cultures: controls 3.04 Matched cohort study DALYs severe pneumonia (VAP) 0.056 Hsieh et al. [9] DALYs severe non-VAP illness 0.037 Hsieh et al. [9] DALYs death 30.5 Hsieh et al. [9] Life expectancy Nicaragua in years 73 PAHO [16]